Objective:

To announce the FDA's approval for the repeat administration of iDose® TR for glaucoma treatment, specifically under updated labeling.

Approach:

Key Findings:

• iDose TR is a long-duration, intracameral therapy delivering travoprost continuously.
• The updated labeling permits re-administration in patients with healthy corneas, defined by specific corneal endothelial cell density parameters.
• Clinical studies show no significant corneal endothelial cell loss over three years, supporting its safety.

Interpretation:

The approval enhances treatment options for glaucoma patients, providing physicians with greater flexibility and confirming iDose TR's established safety profile.

Limitations:

• Re-administration is only for patients with healthy corneas, specifically defined by corneal endothelial cell density parameters.

Conclusion:

The FDA's approval of repeat use for iDose TR supports its role as a safe and effective alternative to traditional glaucoma treatments.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.